International Journal of Medical Science in Clinical Research and Review
Online ISSN: 2581-8945
Available Online at https://ijmscrr.in/ Volume 7|Issue 06 (November-December) |2024 Page: 1303-1308

Original Research Paper

Bronchial asthma: An integrated approach to patient care

Authors:
Hemant Budania[1], Amit Choudhary[1], Komal Lamba[1], Deshraj Lamba[1], Anisha[1], Navita[1], Manoj Kumar Sharma[2], Rajkamal Sharma[3*]

[1]General Medicine Student (Group 3001a), Karaganda Medical University, Karaganda, Kazakhstan
[2]Department of Clinical Pharmacology and Evidence Based Medicine, Karaganda Medical University, Karaganda, Kazakhstan
[3]Department of Morphology, Karaganda Medical University, Karaganda, Kazakhstan

***Corresponding Author**:
Rajkamal Sharma, Department of Morphology, Karaganda Medical University, Karaganda, Kazakhstan

Article Received: 10-October -2024, Revised: 01-November-2024, Accepted: 21-November-2024

ABSTRACT:
Bronchial asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms can range from mild to severe and can significantly impact the quality of life of affected individuals. Asthma not only poses a substantial burden on patients and their families, but also exerts considerable pressure on healthcare systems globally due to its prevalence, morbidity, and the need for ongoing management and treatment. This article aims to explore an integrated approach to patient care in bronchial asthma, encompassing multiple dimensions such as pathophysiology, environmental and genetic factors, diagnosis, and comprehensive management strategies. Understanding the pathophysiology of asthma, including the chronic inflammation and remodeling of the airways, is crucial for developing effective treatment plans (Barnes, 2008). Environmental factors, such as allergens and air pollution, as well as genetic predisposition, play significant roles in the development and exacerbation of asthma symptoms (Brunekreef & Holgate, 2002; Holloway, Yang, & Holgate, 2010). Diagnosis of asthma involves a detailed medical history, physical examination, lung function tests, and identification of specific triggers through allergy testing (Pellegrino et al., 2005). Spirometry is a key diagnostic tool used to measure airflow limitation and its reversibility with bronchodilators. Biomarkers are also increasingly being used to assess and monitor inflammation levels. Management strategies for asthma are multifaceted and include pharmacotherapy, trigger avoidance, patient education, regular monitoring, and lifestyle modifications (Bousquet et al., 2010; NHLBI, 2007). Pharmacotherapy primarily involves the use of inhaled corticosteroids (ICS) to reduce inflammation and prevent exacerbations, with additional medications such as long-acting beta-agonists (LABAs), leukotriene modifiers, and biologics used for more severe cases (Bousquet et al., 2010). Avoiding known triggers, such as allergens and pollutants, is essential in preventing asthma attacks. Educating patients about their condition, proper inhaler techniques, and self-management strategies is vital for improving adherence to treatment and overall disease control (Jones, 2008). Regular monitoring of lung function and routine follow-ups help in adjusting treatment plans and preventing exacerbations (GINA, 2020). Encouraging a healthy lifestyle, including regular physical activity and weight management, can also positively impact asthma control (Pedersen & Saltin, 2006). By adopting a holistic approach to asthma care, healthcare providers can better address the complexities of the disease and improve patient outcomes. Ongoing research and innovation are crucial for developing new therapies and refining existing treatment protocols to enhance the quality of life for individuals living with asthma (Schatz & Rosenwasser, 2014).

Keywords: Bronchial Asthma, Diagnosis, Management, Treatment.

INTRODUCTION:

Asthma affects millions of people worldwide, manifesting in varying degrees of severity and requiring tailored management strategies to achieve optimal control. The disease is characterized by chronic inflammation of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms can significantly impair daily activities and overall quality of life (Barnes, 2008). Traditional asthma management has predominantly focused on symptomatic relief through the use of bronchodilators and anti-inflammatory medications. However, this approach often fails to address the underlying chronic inflammation and does not provide

comprehensive, long-term control of the disease (Holloway, Yang, & Holgate, 2010). Recognizing the limitations of symptom-focused treatments, there is a growing emphasis on adopting a more holistic and integrated approach to asthma care.

An integrated approach to asthma management involves understanding the intricate pathophysiology of the disease, including the roles of genetic predisposition and environmental triggers. It also emphasizes the importance of personalized treatment plans that are tailored to the unique needs and circumstances of each patient. This includes not only pharmacotherapy but also preventive measures, patient education, regular monitoring, and lifestyle modifications (Pellegrino et al., 2005). By empowering patients with knowledge and tools to manage their condition effectively, healthcare providers can improve adherence to treatment regimens, reduce the frequency and severity of asthma exacerbations, and enhance overall quality of life. This comprehensive strategy is essential for managing the complexities of asthma and achieving better patient outcomes in the long term (Jones, 2008; GINA, 2020).

PATHOPHYSIOLOGY OF BRONCHIAL ASTHMA:

Understanding the underlying mechanisms of asthma is crucial for effective treatment. Asthma is characterized by chronic airway inflammation, hyperresponsiveness, and remodeling. The inflammatory process involves various cells and mediators, including eosinophils, mast cells, T lymphocytes, and cytokines, which contribute to airway obstruction and symptoms.

Airway Inflammation: Inflammation in asthma is driven by a complex interplay of genetic and environmental factors, leading to the activation of various inflammatory cells. Eosinophils and T-helper type 2 (Th2) lymphocytes are particularly important. These cells release cytokines such as interleukins (IL-4, IL-5, IL-13) and other mediators that contribute to airway inflammation and hyperresponsiveness (Barnes, 2008; Wenzel, 2012).

Bronchial Hyperresponsivess: This is a hallmark of asthma where the bronchi become excessively responsive to various stimuli. This hyperresponsiveness is due to both the inflammation and the smooth muscle dysfunction in the airways (Barnes, 2008).

Airway Remodeling involves structural changes in the airway walls, including goblet cell hyperplasia, subepithelial fibrosis, collagen deposition, and smooth muscle hypertrophy. These changes result in persistent airflow obstruction and contribute to the chronic nature of the disease (Jeffery, 2001; Elias, Lee, Zheng, & Zhu, 1999).

Bronchoconstraction: In asthma, the dominant physiological event leading to clinical symptoms is airway narrowing and a subsequent interference with airflow. During acute exacerbations, bronchial smooth muscle contraction (bronchoconstriction) occurs quickly, narrowing the airways in response to various stimuli, including allergens or irritants.

Allergen-induced acute bronchoconstriction results from an IgE-dependent release of mediators from mast cells. This includes histamine, tryptase, leukotrienes, and prostaglandins, which directly contract airway smooth muscle (Busse & Lemanske, 2001).

Aspirin and other nonsteroidal anti-inflammatory drugs can also cause acute airflow obstruction in some patients. This non-IgE-dependent response involves mediator release from airway cells (Stevenson & Szczeklik, 2006)

Other stimuli: including exercise, cold air, and irritants, can cause acute airflow obstruction. The mechanisms regulating the airway response to these factors are less well defined, but the intensity of the response appears related to underlying airway inflammation. Stress may also play a role in precipitating asthma exacerbations. The mechanisms involved have yet to be established and may include enhanced generation of pro-inflammatory cytokines.

Understanding the pathophysiology of asthma is crucial for developing targeted therapies and improving patient outcomes.

FACTORS AFFECTING BRONCHIAL ASTHMA:

Bronchial asthma is influenced by a combination of environmental and genetic factors. Understanding these factors is crucial for managing and preventing asthma.

1. Environmental factors

Allergens: Exposure to allergens such as pollen, mold, animal dander, and dust mites can trigger asthma symptoms.

Air Pollution: Both indoor and outdoor air pollution, including tobacco smoke, chemical fumes, and exhaust fumes, can worsen asthma symptoms.

Occupational Exposures: Certain occupational environments with exposure to chemicals, dust, and fumes can increase the risk of developing asthma.

Weather Changes: Cold air, humidity, and changes in weather can also trigger asthma symptoms.

2. Genetics Factors

Family History: Having a family history of asthma increases the likelihood of developing the condition. If one parent has asthma, the risk is higher, and if both parents have asthma, the risk is even greater.

Genetic Predisposition: Genetic predisposition accounts for around 70% of a person's risk for developing asthma. Specific genes have been linked to

asthma, although the exact mechanisms are still being studied.

3. Other Factors

Viral Respiratory Infections: Respiratory infections during infancy and childhood can cause wheezing and may lead to chronic asthma.
Allergic Conditions: Conditions such as eczema (atopic dermatitis) and hay fever (allergic rhinitis) are considered risk factors for developing asthma.
Obesity: Overweight and obesity can increase the risk of asthma, possibly due to low-grade inflammation in the body.
Stress: Stress may play a role in precipitating asthma exacerbations, although the mechanisms involved have yet to be fully established.

DIAGNOSIS OF BRONCHIAL ASTHMA:

Accurate diagnosis involves a combination of medical history, physical examination, lung function tests, and assessment of biomarkers. Spirometry is a key diagnostic tool, measuring the airflow limitation and reversibility with bronchodilators. Identifying specific triggers through allergy testing can also aid in developing targeted management plans.
Medical History: The doctor will ask about symptoms, their frequency, and any triggers or patterns. They will also inquire about family history of asthma or other allergic conditions.
Physical Examination: The doctor will listen to the lungs for signs of wheezing or other abnormalities and check for signs of allergic conditions such as eczema or nasal polyps.
Spirometry: This is the most common test used to diagnose asthma. It measures the amount of air you can exhale and how quickly you can do it. It helps to assess lung function and detect airway obstruction.
Peak Flow Meter: This simple device measures how hard you can breathe out. Lower than normal peak flow readings indicate asthma.
Allergy Testing: Skin or blood tests can identify specific allergens that may trigger asthma symptoms
Methacholine Challenge Test: This test involves inhaling a substance that can cause airway narrowing. If your airways react, it suggests asthma.
Sputum Eosinophils: A test to measure the number of eosinophils (a type of white blood cell) in your sputum, which can indicate inflammation associated with asthma.
Imaging Tests: Chest X-rays or CT scans may be used to rule out other conditions.

MANAGEMENT STRATEGIES WITH INTEGRATED APPROACH:

An integrated approach to asthma care includes:

Pharmacotherapy: Inhaled corticosteroids (ICS) are the cornerstone of asthma management, reducing inflammation and preventing exacerbations. Long-acting beta-agonists (LABAs), leukotriene modifiers, and biologics are used for more severe cases. ICS are the most effective long-term control medications for asthma. They reduce inflammation in the airways and help prevent asthma attacks.
Long-Acting Beta-Agonists (LABAs): These medications help to keep the airways open for longer periods and are often used in combination with inhaled corticosteroids.
Short-Acting Beta-Agonists (SABAs): These are quick-relief medications used to relieve acute asthma symptoms.
Leukotriene Modifiers: These oral medications help to reduce inflammation and are used for patients who cannot use inhaled corticosteroids.
Anticholinergics: These medications help to relax the muscles around the airways and are often used in combination with other asthma medications.
Biologic Therapies: These are newer treatments that target specific molecules involved in the inflammatory process and are used for severe asthma.
Mast Cell Stabilizers: These medications help to prevent the release of histamine and other chemicals that cause inflammation.
Methylxanthines: These are oral medications that help to relax the muscles around the airways and reduce inflammation.

Life style Changes:

Trigger Avoidance: Identifying and avoiding environmental triggers, such as allergens and pollutants, is crucial in preventing asthma attacks.
Exercise: Engaging in regular physical activity to improve overall lung function and health.
Healthy Diet: Eating a balanced diet rich in fruits, vegetables, and whole grains to support overall health.
Stress Management: Practicing stress-reducing techniques such as yoga, meditation, or deep breathing exercises.
Patient Education: Empowering patients with knowledge about their condition, proper inhaler techniques, and self-management strategies can improve adherence to treatment and control.
Supportive therapies:
Breathing Exercises: Techniques such as the Papworth method and the Buteyko method can help improve breathing patterns and reduce asthma symptoms.

Acupuncture: Some patients find relief from asthma symptoms through acupuncture.
Traditional Chinese Herbal Medicine: Certain herbal remedies may help to reduce asthma symptoms, but should be used under the guidance of a healthcare professional.

CONCLUSION:

Integrated approach to patient care in bronchial asthma is indeed fundamental for managing this multifaceted condition. By addressing the pathophysiological aspects, including chronic inflammation and airway remodeling, as well as the environmental and genetic factors, healthcare providers can tailor treatments to the unique needs of each patient. This holistic strategy not only enhances the effectiveness of management but also significantly improves the quality of life for those affected by asthma.

By incorporating comprehensive management strategies—such as personalized pharmacotherapy, patient education, regular monitoring, and environmental control—providers can reduce the frequency and severity of asthma attacks, ensuring better overall health outcomes. Additionally, ongoing research and innovation are essential for developing new therapeutic approaches and refining existing protocols, thereby offering hope for even more effective treatments in the future.

By fostering collaboration among healthcare professionals, involving patients in their own care decisions, and continuously adapting to the latest medical advancements, the integrated approach ensures that asthma care remains dynamic and responsive to the evolving needs of patients.

CONFLICTS OF INTEREST: No

REFERENCES:

1. Barnes, P. J. (2008). Immunology of asthma and chronic obstructive pulmonary disease. *Nature Reviews Immunology*, *8*(3), 183-192.
2. Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., ... & Zuberbier, T. (2010). Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy*, *63*(S86), 8-160.
3. Brunekreef, B., & Holgate, S. T. (2002). Air pollution and health. *The Lancet*, *360*(9341), 1233-1242.
4. Global Initiative for Asthma (GINA). (2020). Global strategy for asthma management and prevention. Retrieved from GINA.
5. Holloway, J. W., Yang, I. A., & Holgate, S. T. (2010). Genetics of allergic disease. *Journal of Allergy and Clinical Immunology*, *125*(2), S81-S94.
6. Jones, C. A. (2008). Asthma in children: Diagnosis and management. *British Medical Journal*, *336*(7644), 706-710.
7. National Heart, Lung, and Blood Institute (NHLBI). (2007). Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. *Journal of Allergy and Clinical Immunology*, *120*(5 Suppl), S94-S138.
8. Pedersen, B. K., & Saltin, B. (2006). Evidence for prescribing exercise as therapy in chronic disease. *Scandinavian Journal of Medicine & Science in Sports*, *16*(Suppl 1), 3-63.
9. Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., ... & Wanger, J. (2005). Interpretative strategies for lung function tests. *European Respiratory Journal*, *26*(5), 948-968.
10. Schatz, M., & Rosenwasser, L. (2014). The allergic asthma phenotype. *Journal of Allergy and Clinical Immunology: In Practice*, *2*(6), 645-658.
11. Simpson, J. L., Grissell, T. V., Douwes, J., Scott, R. J., & Gibson, P. G. (2007). Innate

immune activation in neutrophilic asthma and bronchiectasis. *Thorax, 62*(3), 211-218.

12. Szefler, S. J., & Wenzel, S. E. (2006). Bronchial thermoplasty for asthma. *Chest, 130*(3), 711-712.
13. Tschernig, T., & Pabst, R. (2000). Bronchus-associated lymphoid tissue (BALT) is not a major source of memory B cells for the bronchial system. *European Respiratory Journal, 15*(2), 328-330.
14. van der Zee, J. S., & Holgate, S. T. (1994). Cytokine network in asthma and chronic obstructive pulmonary disease: Clinical implications. *International Archives of Allergy and Immunology, 105*(3), 211-223.
15. Wenzel, S. E. (2012). Asthma phenotypes: The evolution from clinical to molecular approaches. *Nature Medicine, 18*(5), 716-725.
16. Barnes, P. J. (2008). Immunology of asthma and chronic obstructive pulmonary disease. *Nature Reviews Immunology, 8*(3), 183-192.
17. Elias, J. A., Lee, C. G., Zheng, T., & Zhu, Z. (1999). New insights into the pathogenesis of asthma. *The Journal of Clinical Investigation, 104*(8), 1001-1006.
18. Jeffery, P. K. (2001). Remodeling in asthma and chronic obstructive lung disease. *American Journal of Respiratory and Critical Care Medicine, 164*(10 Pt 2), S28-S38.
19. Wenzel, S. E. (2012). Asthma phenotypes: The evolution from clinical to molecular approaches. *Nature Medicine, 18*(5), 716-725.
20. Busse, W. W., & Lemanske, R. F. Jr. (2001). Asthma. *The New England Journal of Medicine, 344*(5), 350-362.
21. Stevenson, D. D., & Szczeklik, A. (2006). Clinical and pathologic perspectives on aspirin sensitivity and asthma. *Journal of Allergy and Clinical Immunology, 118*(4), 773-786.
22. Wang, Z., Li, Y., Gao, Y., Fu, Y., Lin, J., Lei, X., Zheng, J., & Jiang, M. (2023). Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Respiratory Research, 24*(3), 169. https://doi.org/10.1186/s12931-023-02475-6
23. api, A., Blasi, F., Canonica, G. W., Morandi, L., Richeldi, L., & Rossi, A. (2020). Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy, Asthma & Clinical Immunology, 16*(1), 75. https://doi.org/10.1186/s13223-020-00472-8
24. Trivedi, M., & Denton, E. (2019). Asthma in Children and Adults—What Are the Differences and What Can They Tell Us About Asthma? *Frontiers in Pediatrics, 7*(2), 256. https://doi.org/10.3389/fped.2019.00256
25. Mayo Clinic. (2024). Asthma - Diagnosis and treatment. Retrieved from https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660
26. American Lung Association. (2024). How is asthma diagnosed? Retrieved from https://www.lung.org/lung-health-diseases/lung-

disease-lookup/asthma/symptoms-diagnosis/how-is-asthma-diagnosed

27. Cleveland Clinic. (2024). Asthma: Types, causes, symptoms, diagnosis & treatment. Retrieved from https://my.clevelandclinic.org/health/diseases/6424-asthma
28. WebMD. (2023). Bronchial asthma treatments, symptoms, causes, and more. Retrieved from https://www.webmd.com/asthma/bronchial-asthma
29. Global Initiative for Asthma (GINA). (2020). *Pocket Guide for Asthma Management and Prevention*. Retrieved from https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf
30. National Heart, Lung, and Blood Institute (NHLBI). (2020). *2020 Focused Updates to the Asthma Management Guidelines: Clinician's Guide*. Retrieved from https://ginasthma.org/wp-content/uploads/2019/02/GINA-Implementation-Pocket-Guide-2019.pdf
31. European Respiratory Journal. (2020). An integrated asthma care pathway: a simple multifunctional tool to facilitate safe early hospital discharge and improved follow-on care in the community. Retrieved from https://erj.ersjournals.com/content/54/suppl_63/PA3954.